Compare MCHB & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCHB | IMNM |
|---|---|---|
| Founded | 1905 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | N/A | 2020 |
| Metric | MCHB | IMNM |
|---|---|---|
| Price | $14.51 | $23.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $15.75 | ★ $32.80 |
| AVG Volume (30 Days) | 450.3K | ★ 839.6K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.53% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | $43.32 | N/A |
| Revenue Next Year | N/A | $1,127.34 |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.82 | $7.15 |
| 52 Week High | $16.02 | $27.65 |
| Indicator | MCHB | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 40.31 | 52.81 |
| Support Level | $13.89 | $19.23 |
| Resistance Level | $15.69 | $25.10 |
| Average True Range (ATR) | 0.48 | 0.98 |
| MACD | -0.13 | -0.10 |
| Stochastic Oscillator | 37.28 | 33.94 |
Mechanics Bancorp is an independent, full-service community bank. It provides personal banking, business banking, trust and estate, brokerage and wealth management services. its retail banking products include personal checking, savings, and loan products (including credit card, home equity, home mortgage, and secured/unsecured loans), online banking, and wealth management services (including trust and estate, investment management, and financial planning services). its banking products and services for businesses include business checking and savings accounts, business debit cards, online banking, cash management services, wealth management services, business credit cards, commercial real estate loans, equipment leasing, and loans guaranteed by the Small Business Administration.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.